Halberd Corporation (HALB)
Halberd Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Jackson Center, PA, US. The stock last traded at $0.00, down 6.67% on the session, giving a market capitalisation of $433,335. On trailing twelve-month figures it carries a trailing P/E of -13.35, a net margin of 0.0%. Its beta of 0.13 implies it has historically moved less than the broad market.
Halberd Corporation is a biotechnology firm dedicated to pioneering therapies for neurodegenerative conditions. The company's therapeutic focus encompasses a broad range of serious illnesses, including post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, various forms of cancer, and disorders impacting the blood and cerebrospinal fluid. Established in 2009, Halberd Corporation operates from its headquarters in Jackson Center, Pennsylvania.
Halberd Corporation is most often compared with the following Healthcare names: